Efficacy
After a median follow up of 24 months, the median PFS was 12.4 months in the GC+BV arm compared with 8.4 months in GC+PL arm (HR=0.484, 95% CI 0.388 to 0.605, log-rank p < 0.0001).r
The ORR was significantly higher in the GC+BV group than in the GC+PL group (78.5% versus 57.4%, p<0.0001). The DoR was 10.4 months versus 7.4 months in the GC+BV and GC+PL arms, respectively (HR=0.534, 95% CI 0.408 to 0.698).r
After a median follow up of 58.2 months in the GC+BV group and 56.4 months in the GC+PL group, the median OS was not significantly different between arms (33.6 months versus 32.9 months; HR=0.95, 95% CI 0.77 to 1.18, log-rank p=0.65).r
Kaplan-Meier curve of progression-free survivalr
© J Clin Oncol 2012
Kaplan-Meier curve of overall survivalr
© Gynecol Oncol 2015